← Back to patent-cliff list
JNJ-88545223
Tier C — Watch / tradeJNJ-88545223
Janssen Research & Development Llc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Psoriatic arthritis
Regional status
US
Phase II
2026-01-15
EU
Phase II
2026-01-15
China
Phase II
2026-01-15
Japan
Phase II
2026-01-15
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of JNJ-88545223?
Approved indications include: Psoriatic arthritis.
When does the JNJ-88545223 patent expire?
No public expiry year is available for JNJ-88545223 yet; this page updates once verified.
How do I get a quote for JNJ-88545223 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29